Page 28 - Read Online

Page 10 of 11 Mathieu et al. Metab Target Organ Damage 2022;2:15 https://dx.doi.org/10.20517/mtod.2022.16

PubMed PMC
28. Bonifacio E, Achenbach P. Birth and coming of age of islet autoantibodies. Clin Exp Immunol 2019;198:294-305. DOI PubMed
PMC
29. Vehik K, Bonifacio E, Lernmark Å, et al; TEDDY Study Group. Hierarchical order of distinct autoantibody spreading and progression
to type 1 diabetes in the TEDDY study. Diabetes Care 2020;43:2066-73. DOI PubMed PMC
30. Ghalwash M, Dunne JL, Lundgren M, et al. Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort
study. Lancet Diabetes Endocrinol 2022;10:589-96. DOI PubMed
31. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine
Society, and the American Diabetes Association. Diabetes Care 2015;38:1964-74. DOI PubMed PMC
32. Mathieu C. Are We There Yet? Finding ways to work together on T1D. Diabetes Care 2018;41:667-9. DOI PubMed
33. Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O. Lessons to learn from low-dose cyclosporin-A: a new approach for
unexpected clinical applications. Front Immunol 2019;10:588. DOI PubMed PMC
34. Jacobsen LM, Bundy BN, Greco MN, et al. Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes.
Diabetes Technol Ther 2020;22:948-53. DOI PubMed PMC
35. Gitelman SE, Gottlieb PA, Felner EI, et al; ITN START Study Team. Antithymocyte globulin therapy for patients with recent-onset
type 1 diabetes: 2 year results of a randomised trial. Diabetologia 2016;59:1153-61. DOI PubMed PMC
36. Haller MJ, Long SA, Blanchfield JL, et al; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Low-dose anti-thymocyte globulin
preserves C-peptide, reduces HbA , and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year
1c
clinical trial data. Diabetes 2019;68:1267-76. DOI PubMed PMC
37. Haller MJ, Schatz DA, Skyler JS, et al; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Low-dose Anti-Thymocyte Globulin
(ATG) preserves β-cell function and improves HbA in new-onset type 1 diabetes. Diabetes Care 2018;41:1917-25. DOI PubMed
1c
PMC
38. Lu Y, Suzuki J, Guillioli M, Umland O, Chen Z. Induction of self-antigen-specific Foxp3+ regulatory T cells in the periphery by
lymphodepletion treatment with anti-mouse thymocyte globulin in mice. Immunology 2011;134:50-9. DOI PubMed PMC
39. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med
2002;346:1692-8. DOI PubMed
40. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N
Engl J Med 2005;352:2598-608. DOI PubMed
41. Chatenoud L. A future for CD3 antibodies in immunotherapy of type 1 diabetes. Diabetologia 2019;62:578-81. DOI PubMed
42. Aronson R, Gottlieb PA, Christiansen JS, et al; DEFEND Investigator Group. Low-dose otelixizumab anti-CD3 monoclonal antibody
DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014;37:2746-54.
DOI PubMed PMC
43. Ambery P, Donner TW, Biswas N, Donaldson J, Parkin J, Dayan CM. Efficacy and safety of low-dose otelixizumab anti-CD3
monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled,
double-blind, multi-centre study. Diabet Med 2014;31:399-402. DOI PubMed
44. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a
randomised, placebo-controlled trial. Lancet 2011;378:487-97. DOI PubMed PMC
45. Hagopian W, Ferry RJ Jr, Sherry N, et al; Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes:
two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013;62:3901-8. DOI PubMed PMC
46. Perdigoto AL, Preston-Hurlburt P, Clark P, et al; Immune Tolerance Network. Treatment of type 1 diabetes with teplizumab: clinical
and immunological follow-up after 7 years from diagnosis. Diabetologia 2019;62:655-64. DOI PubMed PMC
47. Herold KC, Bundy BN, Long SA, et al; Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk
for type 1 diabetes. N Engl J Med 2019;381:603-13. DOI PubMed PMC
48. Sims EK, Bundy BN, Stier K, et al; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in
antibody-positive high-risk individuals. Sci Transl Med 2021;13:eabc8980. DOI PubMed PMC
49. Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol
2019;19:734-46. DOI PubMed
50. Quattrin T, Haller MJ, Steck AK, et al; T1GER Study Investigators. Golimumab and beta-cell function in youth with new-onset type 1
diabetes. N Engl J Med 2020;383:2007-17. DOI PubMed
51. Ludvigsson J. Autoantigen treatment in type 1 diabetes: unsolved questions on how to select autoantigen and administration route. Int
J Mol Sci 2020;21:1598. DOI PubMed PMC
52. Mathieu C. AG019 ActoBiotics as monotherapy or in association with teplizumab in recent-onset type 1 diabetes was safe and
demonstrated encouraging metabolic and immunological effects. Abstract at EASD 57th Annual meeting. 2021. Available from:
https://investors.precigen.com/events/event-details/european-association-study-diabetes-easd-57th-annual-meeting/ [Last accessed on
15 Sep 2022].
53. Takiishi T, Cook DP, Korf H, et al. Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting lactococcus
lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells. Diabetes 2017;66:448-59. DOI
PubMed
54. Cook DP, Cunha JPMCM, Martens PJ, et al. Intestinal delivery of proinsulin and IL-10 via lactococcus lactis combined with low-dose